Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: twt who wrote (544)	11/13/1998 6:24:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

twt, Enbrel is in a different class of drug, and is not a direct competitor of the COX-2 inhibitors. Enbrel was approved by the FDA last week, yet the stock (IMNX) only moved big time this week, and especially today when it is up more than $6 when the research study was presented at the ACR meeting. It takes time for the news to sink in and for investors to jump on board. You can invest in IMNX last week after the FDA approval was given and you can still make good money. With MTC, you can either take a more speculative approach and buy at the present price or take a more conservative approach and wait until the FDA advisory committee's recommendation (or even after final FDA approval) to average up. There are many drug companies developing COX-2 inhibitors, but MTC and MRK are the frontrunners. We must expect competition in any drug, but first one out always has an advantage over the others, and Pfizer will be able to market the drug properly; there's no worry in that area. Sometimes it's not the best product that makes the most money, it's the best marketed product. Prozac is still a blockbuster drug for LLY though it has been out so many years already and its patent is near expiry (and there are lots of newer antidepressants around). I don't think there'll be any leaking. Any speculation that the drug will be recommended by the Adv. Committee is based on the positive research data on the drug released so far. Anthony

To: twt who wrote (544)	11/15/1998 7:50:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

American Home Products May Make Bid for Monsanto, Forbes Says Bloomberg News November 15, 1998, 6:36 p.m. ET New York, Nov. 15 (Bloomberg) -- American Home Products may again be eyeing Monsanto, barely one month after the two canceled their proposed $35 billion merger, Forbes reported in its ''Streetwalker'' column. American Home's Chief Executive Officer John Stafford has gotten a closer look at Monsanto's pipeline and likes what he sees and is planning to launch an unfriendly bid that would, among other things, dump Monsanto Chief Executive Officer Robert Shapiro. The original deal would have had American Home Products buying Monsanto for stock and winding up with 65 percent control of the company, Forbes said. St. Louis-based Monsanto and Madison, New Jersey-based American Home Products canceled their merger Oct. 14, after company executives, analysts said, could not agree on who would control the company. (Forbes 11/30 365 www.forbes.com